BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 12753271)

  • 1. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
    D'Haese PC; Spasovski GB; Sikole A; Hutchison A; Freemont TJ; Sulkova S; Swanepoel C; Pejanovic S; Djukanovic L; Balducci A; Coen G; Sulowicz W; Ferreira A; Torres A; Curic S; Popovic M; Dimkovic N; De Broe ME
    Kidney Int Suppl; 2003 Jun; (85):S73-8. PubMed ID: 12753271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up.
    Spasovski GB; Sikole A; Gelev S; Masin-Spasovska J; Freemont T; Webster I; Gill M; Jones C; De Broe ME; D'Haese PC
    Nephrol Dial Transplant; 2006 Aug; 21(8):2217-24. PubMed ID: 16595583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease.
    Freemont AJ; Hoyland JA; Denton J;
    Clin Nephrol; 2005 Dec; 64(6):428-37. PubMed ID: 16370155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia.
    Shigematsu T; Tokumoto A; Nakaoka A; Arisaka H
    Ther Apher Dial; 2011 Apr; 15(2):176-84. PubMed ID: 21426511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years.
    Malluche HH; Siami GA; Swanepoel C; Wang GH; Mawad H; Confer S; Smith M; Pratt RD; Monier-Faugere MC;
    Clin Nephrol; 2008 Oct; 70(4):284-95. PubMed ID: 18826853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study.
    Hutchison AJ; Maes B; Vanwalleghem J; Asmus G; Mohamed E; Schmieder R; Backs W; Jamar R; Vosskühler A
    Nephron Clin Pract; 2006; 102(2):c61-71. PubMed ID: 16224198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and baseline characteristics of the LANDMARK study.
    Ogata H; Fukagawa M; Hirakata H; Kaneda H; Kagimura T; Akizawa T;
    Clin Exp Nephrol; 2017 Jun; 21(3):531-537. PubMed ID: 27405619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial.
    Toussaint ND; Lau KK; Polkinghorne KR; Kerr PG
    Nephrology (Carlton); 2011 Mar; 16(3):290-8. PubMed ID: 21342323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial.
    Wada K; Wada Y
    Ther Apher Dial; 2014 Aug; 18(4):353-60. PubMed ID: 24417760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
    Shigematsu T;
    Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.
    Takeuchi K; Matsuda E; Sekino M; Hasegawa Y; Kamo Y; Kikuchi N; Sekino H
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():15-21. PubMed ID: 23586508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
    Lee YK; Choi HY; Shin SK; Lee HY
    Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
    Toida T; Fukudome K; Fujimoto S; Yamada K; Sato Y; Chiyotanda S; Kitamura K
    Clin Nephrol; 2012 Sep; 78(3):216-23. PubMed ID: 22874110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study.
    Ohtake T; Kobayashi S; Oka M; Furuya R; Iwagami M; Tsutsumi D; Mochida Y; Maesato K; Ishioka K; Moriya H; Hidaka S
    J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):439-46. PubMed ID: 23615577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
    Chiang SS; Chen JB; Yang WC
    Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
    Ogata H; Fukagawa M; Hirakata H; Kagimura T; Fukushima M; Akizawa T;
    JAMA; 2021 May; 325(19):1946-1954. PubMed ID: 34003226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate.
    Hutchison AJ; Maes B; Vanwalleghem J; Asmus G; Mohamed E; Schmieder R; Backs W; Jamar R; Vosskuhler A
    Nephron Clin Pract; 2005; 100(1):c8-19. PubMed ID: 15809508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
    Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of lanthanum carbonate on bone markers and bone mineral density in incident hemodialysis patients.
    Goto K; Goto S; Fujii H; Watanabe K; Kono K; Nishi S
    J Bone Miner Metab; 2019 Nov; 37(6):1075-1082. PubMed ID: 31214836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.